FIGURE 3.

The impact of concomitant users of proton pump inhibitor (PPI) and antibiotic (Abs) on object response rates (ORRs), immune‐related adverse events (irAEs), and prognosis in patients treated with immune checkpoint inhibitor (ICI) therapy. ORRs were compared among the non‐users (no PPI and no Abs), single users (PPI or Abs), and double users (PPI and Abs) (A). Occurrences of irAEs were compared among the non‐users, single users, and double users (B). Unadjusted comparison of progression‐free survival (PFS) (C) and OS (D) after ICI therapy among the non‐users, single users, and double users